CGTX logo

Cognition Therapeutics, Inc. Common Stock


CGTX: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.


Show CGTX Financials

Consumer Interest
SEC Filings

Recent trades of CGTX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by CGTX's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of CGTX in WallStreetBets Daily Discussion


Recent insights relating to CGTX

CNBC Recommendations

Recent picks made for CGTX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CGTX

Corporate Flights

Flights by private jets registered to CGTX